Report Overview

The global Sarcoglycanopathies drugs market size is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Limb-Girdle Muscular Dystrophy (LGMD) encompasses heterogeneous group of rare, genetic, degenerative muscle disorders; with both childhood and adult-onset dystrophy. It is a genetically inherited condition that primarily affects skeletal muscle leading to progressive, predominantly proximal muscle weakness at presentation caused by a loss of muscle fibers. It is also estimated that, over the forecast period, the Sarcoglycanopathies treatment market will witness a moderate growth. Treatment mainly focuses on managing the medical and developmental issues



Market Drivers

The Sarcoglycanopathies treatment market is expected to grow over the forecast period, due to increasing research activities and R&D expenditure. Government initiatives in developing new treatment options for Sarcoglycanopathies are expected to drive the growth of the global Sarcoglycanopathies treatment market over the forecast period 2019-2028. Furthermore, the effectiveness of the treatment by reducing the effect of the symptoms is also driving the growth of the global Sarcoglycanopathies treatment market. Improvements in thehealthcare sectorare further facilitating the growth of the Sarcoglycanopathies treatment market, globally. At present, there is no cure and no FDA approved therapies for the treatment of Limb-Girdle Muscular Dystrophy (LGMD), current research is mostly focused on the use of novel gene therapies to treat the underlying genetic changes